Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial ...
The American Journal of Managed Care1d
Cilta-cel Leads to Prolonged Progression-Free Survival in Multiple Myeloma
Yi Lin, MD, PhD, hematologist and oncologist, Mayo Clinic, discusses the efficacy of ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor T-cell therapy vs standard treatments for patients ...
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...
Too Old to Operate2d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Medscape4d
IVIG Prophylaxis in Multiple Myeloma Cuts Infections, Boosts Survival
IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...
Too Old to Operate6d
Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer
Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or ...
Cure Today4d
Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL
Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...
oncnursingnews2d
Daratumumab Monotherapy Shows Survival Benefit in Smoldering Myeloma
Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.
PharmiWeb3d
DARZALEX® (daratumumab) SC-based regimens improve…
Janssen-Cilag International NV, a Johnson & Johnson company, announced data highlighting that DARZALEX® (daratumumab) subcutaneous (SC)-based regimens improve overall and sustained minimal residual ...